用精神药物治疗杜氏肌肉衰竭中神经行为问题的治疗:使用真实世界的数据进行了一项描述性研究
Pien M M Weerkamp1, Sam Geuens2, Philippe Collin3
1Kempenhaege, Centre for Neurological Learning Disabilities, Heeze, the Netherlands; School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Neuromuscular disorders : NMD
|July 15, 2023
概括
精神药物治疗可以改善杜氏肌肉发育不良 (DMD) 患者的神经行为症状. 甲基化物显示出最多的改善,但需要进一步的研究来确定最佳的治疗策略.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 遗传学 遗传学 是一个
背景情况:
- 杜申肌肉发育不良 (DMD) 患者经常经历神经行为问题.
- 对于这些困难的有效治疗方法的证据有限.
研究的目的:
- 在DMD患者中描述心理药物治疗的临床经验.
- 评估各种精神药物的疗效和副作用.
主要方法:
- 52名DMD患者接受心理药物治疗的描述性研究 (2008-2022年).
- 从电子患者档案中收集的数据,包括症状,药物和结果.
- 临床全球印象 (CGI) 尺度用于评估症状严重程度和变化.
主要成果:
- 55.8%的患者有四种或更多的并发性神经行为症状.
- 甲基化物在54.2%的患者中改善了CGI得分.
- 素和素分别在38.9%和22.2%的患者中显示出改善,副作用最小.
结论:
- 精神药物可以有效地管理DMD患者的神经行为症状.
- 甲基胺似乎是最有效的,但需要进一步的研究.
- 了解DMD中精神药物治疗需要进一步的研究.
相关概念视频
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Drug Therapy
73
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
73


